^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
DEEPGEN™ Panel

Company:
Quantgene
Type:
Laboratory Developed Test
Evidence

News

2ms
Effect of cancer screening with multi-cancer early detection testing and whole body MRI on cancer worry in a high-risk population. (ASCO 2024)
MCED and WBM testing is feasible and was associated with decreased cancer worry at 6 months. In this high-risk cohort, cancer was detected in 4% of patients. Further evaluation of cancer screening in high-risk populations using WBM and MCED testing is warranted particularly with respect to patient-centered outcomes, cancer outcomes, and healthcare resource utilization.
Clinical
|
JAK2 (Janus kinase 2)
|
DEEPGEN™ Panel
5ms
Feasibility of Whole Body MRI and Multicancer Early Detection Testing in People at High Risk for Cancer Development (ACMG 2024)
MCED and whole-body MRI testing is feasible in people at high-risk for cancer development based on age, family history, and germline variant status. Testing detected cancer at a relatively high prevalence. Additional research on the benefits of whole-body imaging and MCED testing, including effects on cancer mortality and cancer worry are needed.
BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • JAK2 (Janus kinase 2) • MSH2 (MutS Homolog 2) • CDH1 (Cadherin 1) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • MUTYH (MutY homolog) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
|
DEEPGEN™ Panel